STOCK TITAN

Aridis Pharmaceuticals Inc - ARDS STOCK NEWS

Welcome to our dedicated news page for Aridis Pharmaceuticals (Ticker: ARDS), a resource for investors and traders seeking the latest updates and insights on Aridis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aridis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aridis Pharmaceuticals's position in the market.

Rhea-AI Summary
Aridis Pharmaceuticals, Inc. (ARDS) has announced the adjournment of its 2023 Annual Meeting of Stockholders due to lack of the requisite quorum, rescheduled for January 12, 2024. The company urges stockholders to vote on the proposals set forth in the definitive proxy statement on Schedule 14A. Stockholders as of November 2, 2023, can vote, even if they have sold their shares, and are encouraged to read the proxy materials available on the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aridis Pharmaceuticals, Inc. has received two grant awards from the National Institute of Allergy and Infectious Diseases (NIAID) division of the National Institutes of Health (NIH). The grants will be used to develop pan-coronavirus human monoclonal antibodies and antibacterial monoclonal antibodies. The company's COVID-19 monoclonal antibody program showed positive efficacy data in non-human primates. Aridis Pharmaceuticals has also been uplisted to the OTCQB market and raised $2.0 million through the issuance and sale of common stock and warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.09%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with Aridis Pharmaceuticals, Genetic Technologies Limited, and American Resources Corporation on The RedChip Money Report®, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.41%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with Aridis Pharmaceuticals, Genetic Technologies Limited, and American Resources Corporation on The RedChip Money Report®, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Aridis Pharmaceuticals, Genetic Technologies Limited, and American Resources Corporation on The RedChip Money Report®, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
Aridis Pharmaceuticals, Inc. (OTC: ARDS) Announces Pricing of 10 Million Share Offering at $0.20 Per Share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.3%
Tags
none
-
Rhea-AI Summary
Aridis Pharmaceuticals has received positive feedback from the European Medicines Agency (EMA) regarding its proposed Phase 3 study for AR-301, an investigational monoclonal antibody candidate. The study aims to evaluate the efficacy of AR-301 as an adjunctive therapy for pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients. The EMA has agreed to the study design, including the primary efficacy endpoint of Clinical Cure on Day 21. The magnitude of absolute efficacy was higher in older adults, with a +34% improvement on Day 21 and +38% improvement on Day 28 compared to +11% improvement in the overall population. The EMA also approved the expansion of the study to include ventilated hospital acquired pneumonia and ventilated community acquired pneumonia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.91%
Tags
clinical trial
Rhea-AI Summary
Aridis Pharmaceuticals has been granted QIDP designation by the FDA for its AR-301 monoclonal antibody, which is in Phase 3 clinical development as a treatment for pneumonia caused by gram-positive Staphylococcus aureus. This designation provides priority review status and accelerates the drug development and regulatory review processes. The company received positive feedback from the FDA on its proposed Phase 3 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.75%
Tags
none
Aridis Pharmaceuticals Inc

OTC:ARDS

ARDS Rankings

ARDS Stock Data

3.33M
37.24M
18.8%
10.51%
5.55%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Los Gatos

About ARDS

aridis is a privately held infectious diseases focused company in san jose, ca, usa. aridis’ advanced formulation and delivery technologies are combined with proprietary products portfolio to create potent drug candidates that are packaged into convenient to administer, "ready-to-use" formats.